Case-control study of 72 estab. & 56 early RA pts the diagnostic performance of 14-3-3η testing showed AUC ≥0.85 for early & estab.RA. Early RA, -CCP had better specificity (96.4%) and a positive likelihood ratio (21.2%), while 14-3-3η had higher sensitivity (88.1%) https://t.co/jaUux9quy6

3 Months of Romosozumab in Postmenopausal Osteoporosis A report in The Lancet Diabetes & Endocrinology suggested that 3 months of romosozumab (ROMO) followed by denosumab is as effective at increasing hip bone mineral density (BMD) as the standard 12-month course. https://t.co/6HfGFZqavF

July 2024 survey of 143 women (18-45 yrs) with rheumatic disease shows only 63% used effective contraception. In those previously pregnant, 33% experienced an unplanned pregnancy, highlighting contraceptive failure. https://t.co/tR6976vmJp https://t.co/1XRkQfWL5r

Early vs Delayed Belimumab in Lupus An economic evaluation of early vs delayed use of the Blys inhibitor, belimumab (BEL), in systemic lupus erythematosus (SLE) has shown both cost-effectiveness and clinical utility of early BEL initiation in active lupus patients. https://t.co/m6NvAWbNjr

Sonelokimab (SLK) is a nanobody that inhibits IL-17A & IL-17F. Press release from Moonlake shows SLK was effective in the phase 2, S-OLARIS study of 26 axial spondyloarthritis pts where 80+% of patients achieved ASAS40 by Week 12 https://t.co/BQjBcvESfe https://t.co/tXRKj8CPbz

Nice simple overview of SCLERITIS. https://t.co/ndnfi6nZuA https://t.co/bzkOgupk7C

Real-world study of 1202 #PsA pts shows that secukinumab retention rates were lower w/ smoking (79%/73%/72% in never/former/current smokers) but not w/ obesity (72%/77%/77% in normal/overweight/obese), Adh HR signif. higher w/ former (1.32) & current smokers (1.27) https://t.co/1REWmod73W

Review of Calcinosis Cutis - Surgical intervent. most effective (excision, curettage, laser ablation, etc). Medical measures inconsistently, partially effective, best if used early & localized (CCB, TCN, probenecid, immunomodulation, biologics, colchicine, NA thiosulfate, & JAKi https://t.co/rv0hQBv6nX

Referral Rules to Live By (2.20.2026) Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow. Highlights include referral rules, combination biologics in psoriasis, and don't use JAK inhibitors in pregnancy. https://t.co/thzetw5jwa https://t.co/HTjWyqFqDZ

Diagnosing and Managing GCA and Takayasu’s Arteritis Giant-cell arteritis (GCA) and Takayasu’s arteritis (TAK) are both large-vessel vasculitides, but each brings its own diagnostic and management challenges. Many of the difficulties overlap because they are rare, https://t.co/ePJqcMjcBA

Peripheral manifestations are inconsistently assessed in axSpA trials. b/tsDMARDs have small-to-mod effects on peripheral Sxs & may be underestimated. Assessments in axSpA RCTs were low for periph arthritis 54%, enthesitis in 64% and dactylitis in only 10% of studies. https://t.co/cCNvU1oZMh

Full read review & update on Rhabdomyolysis. 26K cases/Yr in USA. Muscle damage leading to weakness, myalgias, swelling, myoglobinuria, electrolyte probs, AKI. Causes: 1) exogenous toxins (46%); 2) trauma; 3) myopathies/metabolic muscle dz (10%), infxn. AKI in 46%, & death in https://t.co/E2LcLeMls0